MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciab954

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022

Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.

Madelon Natacha, Lauper Kim, Breville Gautier, Sabater Royo Irène, Goldstein Rachel, Andrey Diego O, Grifoni Alba, Sette Alessandro, Kaiser Laurent, Siegrist Claire Anne, Finckh Axel, Lalive Patrice H, Didierlaurent Arnaud M, Eberhardt Christiane S

СтатьяНаблюдательное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients treated with anti-CD20 therapy are particularly at risk of developing severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 vaccine effectiveness in this population.

METHODS

This prospective observational cohort study assesses humoral and T-cell responses after vaccination with 2 doses of mRNA-based COVID-19 vaccines in patients treated with rituximab for rheumatic diseases or ocrelizumab for multiple sclerosis (n = 37), compared to immunocompetent individuals (n = 22).

RESULTS

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies were detectable in only 69.4% of patients and at levels that were significantly lower compared to controls who all seroconverted. In contrast to antibodies, Spike (S)-specific CD4 T cells were equally detected in immunocompetent and anti-CD20 treated patients (85-90%) and mostly of a Th1 phenotype. Response rates of S-specific CD8 T cells were higher in ocrelizumab (96.2%) and rituximab-treated patients (81.8%) as compared to controls (66.7%). S-specific CD4 and CD8 T cells were polyfunctional but expressed more effector molecules in patients than in controls. During follow-up, 3 MS patients without SARS-CoV-2-specific antibody response had a mild breakthrough infection. One of them had no detectable S-specific T cells after vaccination.

CONCLUSIONS

Our study suggests that patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA COVID-19 vaccines, despite impaired humoral responses. This could play an important role in the reduction of complications of severe COVID-19.

Для цитирования: Madelon Natacha, Lauper Kim, Breville Gautier, Sabater Royo Irène, Goldstein Rachel, Andrey Diego O, Grifoni Alba, Sette Alessandro, Kaiser Laurent, Siegrist Claire Anne, Finckh Axel, Lalive Patrice H, Didierlaurent Arnaud M, Eberhardt Christiane S. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022. DOI: 10.1093/cid/ciab954.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.